These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 36692913)

  • 1. Specific, Fair and Transparent: A Canadian Process for Funding Drugs for Rare Diseases.
    Stevenson H
    Healthc Pap; 2023 Jan; 21(1):28-33. PubMed ID: 36692913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Historical and projected public spending on drugs for rare diseases in Canada between 2010 and 2025.
    Lech R; Chow G; Mann K; Mott P; Malmberg C; Forte L
    Orphanet J Rare Dis; 2022 Oct; 17(1):371. PubMed ID: 36209128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HTA decision-making for drugs for rare diseases: comparison of processes across countries.
    Stafinski T; Glennie J; Young A; Menon D
    Orphanet J Rare Dis; 2022 Jul; 17(1):258. PubMed ID: 35804398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Engaging the Canadian public on reimbursement decision-making for drugs for rare diseases: a national online survey.
    Polisena J; Burgess M; Mitton C; Lynd LD
    BMC Health Serv Res; 2017 May; 17(1):372. PubMed ID: 28549479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health technology assessment and price negotiation alignment for rare disorder drugs in Canada: Who benefits?
    Rawson NSB
    Orphanet J Rare Dis; 2022 Jun; 17(1):218. PubMed ID: 35698235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors associated with positive and negative recommendations for cancer and non-cancer drugs for rare diseases in Canada.
    Nagase FNI; Stafinski T; Sun J; Jhangri G; Menon D
    Orphanet J Rare Dis; 2019 Jun; 14(1):127. PubMed ID: 31174574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Canadians Need Improved Access to Drugs for Rare Diseases, Not More Denial.
    Rawson NSB; Adams J
    Healthc Pap; 2023 Apr; 21(2):4-10. PubMed ID: 37417343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. International Experiences and Made-in-Canada "Social Pharmaceutical Innovations" as Responses to Challenges Facing Drugs for Rare Diseases.
    Douglas CMW
    Healthc Pap; 2023 Jan; 21(1):66-72. PubMed ID: 36692919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A National Approach to Reimbursement Decision-Making on Drugs for Rare Diseases in Canada? Insights from Across the Ponds.
    Short H; Stafinski T; Menon D
    Healthc Policy; 2015 May; 10(4):24-46. PubMed ID: 26142357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alignment of health technology assessments and price negotiations for new drugs for rare disorders in Canada: Does it lead to improved patient access?
    Rawson NSB
    J Popul Ther Clin Pharmacol; 2020 Feb; 27(1):e48-e64. PubMed ID: 32124580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of a policy framework for the public funding of drugs for rare diseases.
    Winquist E; Coyle D; Clarke JT; Evans GA; Seager C; Chan W; Martin J
    J Gen Intern Med; 2014 Aug; 29 Suppl 3(Suppl 3):S774-9. PubMed ID: 25029973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration.
    Chan K; Nam S; Evans B; de Oliveira C; Chambers A; Gavura S; Hoch J; Mercer RE; Dai WF; Beca J; Tadrous M; Isaranuwatchai W
    BMJ Open; 2020 Jan; 10(1):e032884. PubMed ID: 31915169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An evaluation framework for funding drugs for rare diseases.
    Winquist E; Bell CM; Clarke JT; Evans G; Martin J; Sabharwal M; Gadhok A; Stevenson H; Coyle D
    Value Health; 2012; 15(6):982-6. PubMed ID: 22999151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmaceutical expenditure on drugs for rare diseases in Canada: a historical (2007-13) and prospective (2014-18) MIDAS sales data analysis.
    Divino V; DeKoven M; Kleinrock M; Wade RL; Kim T; Kaura S
    Orphanet J Rare Dis; 2016 May; 11(1):68. PubMed ID: 27207271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can Managed Access Agreements Mitigate Evidentiary, Economic and Ethical Issues with Access to Expensive Drugs for Rare Diseases in the Canadian Context?
    McPhail M; Bubela T
    Healthc Pap; 2023 Jan; 21(1):59-65. PubMed ID: 36692918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Challenges in measuring the societal value of orphan drugs: insights from a canadian stated preference survey.
    Dragojlovic N; Rizzardo S; Bansback N; Mitton C; Marra CA; Lynd LD
    Patient; 2015 Feb; 8(1):93-101. PubMed ID: 25586645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determinants of the Cancer Drug Funding Process in Canada.
    Gotfrit J; Jackson A; Shin JJW; Stewart DJ; Mallick R; Wheatley-Price P
    Curr Oncol; 2022 Mar; 29(3):1997-2007. PubMed ID: 35323362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response to "Canadians Need Improved Access to Drugs for Rare Diseases, Not More Denial".
    Sirrs S; Jiwani B; Lun E; Nakagawa B; McFarlane A
    Healthc Pap; 2023 Apr; 21(2):11-12. PubMed ID: 37417344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Oncology Drug Review Times on Public Funding Recommendations.
    Hussain M; Wong C; Taguedong E; Verma S; Mahsin M; Karim S; Lee-Ying R; Ezeife DA
    Curr Oncol; 2023 Aug; 30(8):7706-7712. PubMed ID: 37623039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health technology assessment of drugs for rare diseases: insights, trends, and reasons for negative recommendations from the CADTH common drug review.
    Janoudi G; Amegatse W; McIntosh B; Sehgal C; Richter T
    Orphanet J Rare Dis; 2016 Dec; 11(1):164. PubMed ID: 27908281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.